2,898
edits
Psilocybin: Difference between revisions
m
no edit summary
mNo edit summary |
mNo edit summary |
||
| Line 16: | Line 16: | ||
==== Depression Dosage ==== | ==== Depression Dosage ==== | ||
[[File:Psilocybin depression treatment.png|thumb|'''Figure 3'''. Depression symptom reduction from placebo, low dose and therapeutic dose of psilocybin.]] | [[File:Psilocybin depression treatment.png|thumb|'''Figure 3'''. Depression symptom reduction from placebo, low dose and therapeutic dose of psilocybin.]] | ||
Best practice indicates that a body weight derived dosage of psilocybin of 0.3mg / kg or 25mg should be used<ref>'''Pharmacokinetics of escalating doses of oral psilocybin in healthy adults'''. Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al. Clin Pharmacokinet. (2017) 56:1543–54. </ref>. In the realm of magic mushrooms this is approximately 2.5 grams of dried Psilocybe cubensis. | Best practice indicates that a body weight derived dosage of psilocybin of 0.3mg / kg or 25mg should be used<ref>'''Pharmacokinetics of escalating doses of oral psilocybin in healthy adults'''. Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al. Clin Pharmacokinet. (2017) 56:1543–54. </ref>. In the realm of magic mushrooms this is approximately 2.5 grams of dried ''Psilocybe cubensis''. | ||
These standard doses has been found to have substantially better clinical outcomes than lower doses such 10mg or microdosing<ref>'''Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression'''. Guy M. Goodwin. First published November 3, 2022. N Engl J Med 2022; 387:1637-1648. DOI: 10.1056/NEJMoa2206443. Accessed on 5th November via <nowiki>https://www.nejm.org/doi/full/10.1056/NEJMoa2206443</nowiki></ref> (see '''Figure 3'''). This equates to 10–20µg l–1 psilocin in plasma, which corresponds to ~60% occupancy of serotonin 2A (5-HT2A) receptors in the neocortex of humans.<ref name=":0">'''Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels'''. MK Madsen Neuropsychopharmacology, first published 2019. Accessed on 5th November 2022 via https://www.nature.com/articles/s41386-019-0324-9</ref> | These standard doses has been found to have substantially better clinical outcomes than lower doses such 10mg or microdosing<ref>'''Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression'''. Guy M. Goodwin. First published November 3, 2022. N Engl J Med 2022; 387:1637-1648. DOI: 10.1056/NEJMoa2206443. Accessed on 5th November via <nowiki>https://www.nejm.org/doi/full/10.1056/NEJMoa2206443</nowiki></ref> (see '''Figure 3'''). This equates to 10–20µg l–1 psilocin in plasma, which corresponds to ~60% occupancy of serotonin 2A (5-HT2A) receptors in the neocortex of humans.<ref name=":0">'''Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels'''. MK Madsen Neuropsychopharmacology, first published 2019. Accessed on 5th November 2022 via https://www.nature.com/articles/s41386-019-0324-9</ref> | ||
A heroic dose, which is usually reserved for experienced psychedelic users is considered to be at the upper end of the dosage spectrum — typically around or more than 5 grams of dried psilocybin mushrooms or anywhere from 25 to 40 mg of pure psilocybin. | |||
==== Psychedelic Experience ==== | ==== Psychedelic Experience ==== | ||